Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...

Recommendations

Info

oNet Registry Update March 2005 Hypotensions “per patient” All indications (n = 582 patients) and AMD (n = 355 patients), all age groups 50% 40% 30% 20% 10% 0% 10,8% 12,7% At least 1 therapy with class I hypotension 5,9% 6,6% At least 1 therapy with class II hypotension All indications AMD 1,9% 2,6% At least 1 therapy with class III hypotension
oNet Registry Update March 2005 Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% n = 2793 protocols 87,3% Hypotension per Patient “by by total number occurring with Rheopheresis series” series (AMD) 8,7% 3,2% 0,9% 0,0% 0,0% 0,0% 0,0% 0,0% 93,4% 4,6% 0,3% 0,0% 0,0% 1,7% 0,0% 0,0% 0,0% 97,4% 2,0% 0,0% 0,0% 0,0% 0,6% 0,0% 0,0% 0,0% Class I Class II Class III Without hypotension 1 2 3 4 5 6 7 8 therapies with hypotension
Page 1 and 2: 26th Annual Meeting April 27 - 30,
Page 3 and 4: heopheresis Blood Plasmaseparation
Page 5 and 6: Rheopheresis for AMD Mechanism of A
Page 7 and 8: Rheopheresis for Microcirculatory D
Page 9 and 10: Rheopheresis for AMD www.rheo.com M
Page 11 and 12: Rheopheresis for AMD Regulatory Sta
Page 14 and 15: Adverse events/side effects: Advers
Page 16 and 17: heopherese-zentrum.de o heo.com he
Page 18 and 19: oNet Registry Update March 2005 dve
Page 20 and 21: oNet Registry Update March 2005 dve
Page 24 and 25: oNet Registry Update March 2005 Hyp
Page 26 and 27: hange in ETDRS-Lines ETDRS ETDRS-Li
Page 28: RheoNet - Registry Summary RheoNet-

Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?